Advanced Biomed Inc. (NASDAQ:ADVB) Sees Significant Increase in Short Interest

Advanced Biomed Inc. (NASDAQ:ADVB) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 57,213 shares, an increase of 441.2% from the July 15th total of 10,571 shares. Based on an average daily trading volume, of 8,635,838 shares, the short-interest ratio is currently 0.0 days. Approximately 4.7% of the company’s stock are sold short.

Institutional Trading of Advanced Biomed

An institutional investor recently bought a new stake in Advanced Biomed stock. GSA Capital Partners LLP acquired a new stake in shares of Advanced Biomed Inc. (NASDAQ:ADVB) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 193,323 shares of the company’s stock, valued at approximately $599,000. GSA Capital Partners LLP owned about 11.70% of Advanced Biomed as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Advanced Biomed presently has a consensus rating of “Sell”.

Advanced Biomed Trading Up 15.3%

NASDAQ ADVB traded up $1.16 during mid-day trading on Thursday, reaching $8.76. The stock had a trading volume of 31,578 shares, compared to its average volume of 936,465. The firm has a market cap of $14.45 million, a PE ratio of 1.82 and a beta of -0.39. Advanced Biomed has a 1 year low of $3.61 and a 1 year high of $24.23. The business’s fifty day moving average price is $6.63.

Advanced Biomed (NASDAQ:ADVB) last posted its earnings results on Saturday, May 16th. The company reported ($0.38) EPS for the quarter.

Advanced Biomed Company Profile

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.